Galectin Therapeutics Inc. (GALT)
USD 1.26
(-1.56%)
USD 1.26
(-1.56%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 46.14 Million USD | 116.9% |
| 2022 | 21.27 Million USD | 300.87% |
| 2021 | -10.59 Million USD | 60.91% |
| 2020 | -27.09 Million USD | 42.88% |
| 2019 | -47.44 Million USD | -474.83% |
| 2018 | -8.25 Million USD | -170.32% |
| 2017 | -3.05 Million USD | 80.13% |
| 2016 | -15.36 Million USD | 40.56% |
| 2015 | -25.84 Million USD | 11.27% |
| 2014 | -29.12 Million USD | -177.7% |
| 2013 | -10.48 Million USD | -12.01% |
| 2012 | -9.36 Million USD | -46.38% |
| 2011 | -6.39 Million USD | -8.59% |
| 2010 | -5.89 Million USD | -2247.01% |
| 2009 | -251 Thousand USD | 21.07% |
| 2008 | -318 Thousand USD | 75.89% |
| 2007 | -1.31 Million USD | -130.2% |
| 2006 | 4.36 Million USD | 197.78% |
| 2005 | -4.46 Million USD | 58.28% |
| 2004 | -10.7 Million USD | -40.7% |
| 2003 | -7.6 Million USD | -299.1% |
| 2002 | -1.9 Million USD | -47.07% |
| 2001 | -1.29 Million USD | -897.06% |
| 2000 | -130 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 67.86 Million USD | 15.11% |
| 2024 Q1 | 58.95 Million USD | 27.76% |
| 2023 Q3 | 40.85 Million USD | -3.73% |
| 2023 Q1 | 32.23 Million USD | 51.53% |
| 2023 Q2 | 42.43 Million USD | 31.63% |
| 2023 FY | 46.14 Million USD | 116.9% |
| 2023 Q4 | 46.14 Million USD | 12.95% |
| 2022 Q2 | 5.44 Million USD | 334.83% |
| 2022 Q1 | -2.31 Million USD | 78.13% |
| 2022 FY | 21.27 Million USD | 300.87% |
| 2022 Q3 | 14.01 Million USD | 157.65% |
| 2022 Q4 | 21.27 Million USD | 51.77% |
| 2021 FY | -10.59 Million USD | 60.91% |
| 2021 Q2 | -21.92 Million USD | -5.82% |
| 2021 Q3 | -17.28 Million USD | 21.17% |
| 2021 Q4 | -10.59 Million USD | 38.71% |
| 2021 Q1 | -20.71 Million USD | 23.54% |
| 2020 Q1 | -43.24 Million USD | 8.84% |
| 2020 FY | -27.09 Million USD | 42.88% |
| 2020 Q2 | -40.69 Million USD | 5.9% |
| 2020 Q3 | -32.49 Million USD | 20.15% |
| 2020 Q4 | -27.09 Million USD | 16.61% |
| 2019 Q4 | -47.44 Million USD | 5.68% |
| 2019 Q3 | -50.3 Million USD | 3.28% |
| 2019 Q2 | -52 Million USD | -649.6% |
| 2019 Q1 | -6.93 Million USD | 15.93% |
| 2019 FY | -47.44 Million USD | -474.83% |
| 2018 Q1 | -3.98 Million USD | -30.63% |
| 2018 Q3 | -10.13 Million USD | 3.44% |
| 2018 Q4 | -8.25 Million USD | 18.58% |
| 2018 FY | -8.25 Million USD | -170.32% |
| 2018 Q2 | -10.49 Million USD | -163.21% |
| 2017 Q2 | -9.12 Million USD | 33.11% |
| 2017 Q4 | -3.05 Million USD | 56.12% |
| 2017 FY | -3.05 Million USD | 80.13% |
| 2017 Q1 | -13.64 Million USD | 11.18% |
| 2017 Q3 | -6.95 Million USD | 23.76% |
| 2016 Q3 | -16.05 Million USD | 10.8% |
| 2016 FY | -15.36 Million USD | 40.56% |
| 2016 Q4 | -15.36 Million USD | 4.34% |
| 2016 Q2 | -18 Million USD | 19.47% |
| 2016 Q1 | -22.35 Million USD | 13.5% |
| 2015 Q2 | -26.36 Million USD | 10.18% |
| 2015 Q4 | -25.84 Million USD | -21.23% |
| 2015 Q3 | -21.31 Million USD | 19.13% |
| 2015 Q1 | -29.34 Million USD | -0.76% |
| 2015 FY | -25.84 Million USD | 11.27% |
| 2014 Q2 | -34.42 Million USD | 5.93% |
| 2014 Q4 | -29.12 Million USD | 6.64% |
| 2014 Q3 | -31.2 Million USD | 9.36% |
| 2014 FY | -29.12 Million USD | -177.7% |
| 2014 Q1 | -36.59 Million USD | -248.88% |
| 2013 Q1 | -7.01 Million USD | 25.05% |
| 2013 Q4 | -10.48 Million USD | -7.97% |
| 2013 FY | -10.48 Million USD | -12.01% |
| 2013 Q3 | -9.71 Million USD | -90.53% |
| 2013 Q2 | -5.09 Million USD | 27.34% |
| 2012 Q4 | -9.36 Million USD | 15.33% |
| 2012 Q2 | -13.13 Million USD | 14.26% |
| 2012 Q3 | -11.05 Million USD | 15.77% |
| 2012 FY | -9.36 Million USD | -46.38% |
| 2012 Q1 | -15.31 Million USD | -139.39% |
| 2011 Q3 | -7.94 Million USD | 0.5% |
| 2011 Q4 | -6.39 Million USD | 19.47% |
| 2011 FY | -6.39 Million USD | -8.59% |
| 2011 Q1 | -6.94 Million USD | -17.94% |
| 2011 Q2 | -7.98 Million USD | -14.91% |
| 2010 Q4 | -5.89 Million USD | -109.35% |
| 2010 Q1 | -120 Thousand USD | 52.19% |
| 2010 Q3 | -2.81 Million USD | 1.71% |
| 2010 Q2 | -2.86 Million USD | -2285.83% |
| 2010 FY | -5.89 Million USD | -2247.01% |
| 2009 Q2 | -982 Thousand USD | -14.05% |
| 2009 FY | -251 Thousand USD | 21.07% |
| 2009 Q4 | -251 Thousand USD | 46.37% |
| 2009 Q3 | -468 Thousand USD | 52.34% |
| 2009 Q1 | -861 Thousand USD | -170.75% |
| 2008 Q1 | -3.25 Million USD | -115.82% |
| 2008 Q2 | -1.55 Million USD | 52.26% |
| 2008 Q3 | -816 Thousand USD | 47.49% |
| 2008 Q4 | -318 Thousand USD | 61.03% |
| 2008 FY | -318 Thousand USD | 75.89% |
| 2007 Q1 | -3.72 Million USD | -185.25% |
| 2007 Q4 | 20.57 Million USD | 2484.47% |
| 2007 FY | -1.31 Million USD | -130.2% |
| 2007 Q3 | -863 Thousand USD | 55.65% |
| 2007 Q2 | -1.94 Million USD | 47.73% |
| 2006 FY | 4.36 Million USD | 197.78% |
| 2006 Q3 | 4.4 Million USD | -34.46% |
| 2006 Q2 | 6.71 Million USD | 129.14% |
| 2006 Q1 | 2.93 Million USD | 165.63% |
| 2006 Q4 | 4.36 Million USD | -0.8% |
| 2005 FY | -4.46 Million USD | 58.28% |
| 2005 Q2 | -7.33 Million USD | 19.18% |
| 2005 Q3 | -6 Million USD | 18.2% |
| 2005 Q4 | -4.46 Million USD | 25.59% |
| 2005 Q1 | -9.07 Million USD | 15.19% |
| 2004 Q3 | -12.45 Million USD | -41.91% |
| 2004 Q1 | -6.54 Million USD | 13.99% |
| 2004 Q2 | -8.77 Million USD | -34.12% |
| 2004 FY | -10.7 Million USD | -40.7% |
| 2004 Q4 | -10.7 Million USD | 14.05% |
| 2003 FY | -7.6 Million USD | -299.1% |
| 2003 Q2 | -1.79 Million USD | 16.13% |
| 2003 Q4 | -7.6 Million USD | -58.91% |
| 2003 Q3 | -4.78 Million USD | -167.31% |
| 2003 Q1 | -2.13 Million USD | -12.03% |
| 2002 Q3 | -1.16 Million USD | -72.18% |
| 2002 Q1 | -772.44 Thousand USD | 40.41% |
| 2002 Q4 | -1.9 Million USD | -64.26% |
| 2002 FY | -1.9 Million USD | -47.07% |
| 2002 Q2 | -674 Thousand USD | 12.74% |
| 2001 Q2 | 564.25 Thousand USD | 0.0% |
| 2001 FY | -1.29 Million USD | -897.06% |
| 2001 Q3 | -670.91 Thousand USD | -218.9% |
| 2001 Q4 | -1.29 Million USD | -93.2% |
| 2000 FY | -130 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AbCellera Biologics Inc. | -55.94 Million USD | 182.494% |
| Alkermes plc | -166.73 Million USD | 127.676% |
| Agenus Inc. | 274.13 Million USD | 83.166% |
| Alnylam Pharmaceuticals, Inc. | 1.86 Billion USD | 97.532% |
| Aptorum Group Limited | 1.35 Million USD | -3300.548% |
| Ardelyx, Inc. | 34.51 Million USD | -33.713% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | -978.201% |
| Bicycle Therapeutics plc | -481.46 Million USD | 109.585% |
| BioXcel Therapeutics, Inc. | 36.16 Million USD | -27.608% |
| ChromaDex Corporation | -24.04 Million USD | 291.895% |
| Chimerix, Inc. | -25.51 Million USD | 280.848% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -562.263% |
| Caribou Biosciences, Inc. | -23.67 Million USD | 294.902% |
| CRISPR Therapeutics AG | -150.84 Million USD | 130.592% |
| Precision BioSciences, Inc. | -85.41 Million USD | 154.03% |
| Dyadic International, Inc. | -6.37 Million USD | 823.523% |
| Eton Pharmaceuticals, Inc. | -15.93 Million USD | 389.632% |
| Fortress Biotech, Inc. | 7.66 Million USD | -502.048% |
| Lantern Pharma Inc. | -21.7 Million USD | 312.627% |
| HOOKIPA Pharma Inc. | -110.53 Million USD | 141.748% |
| Inhibikase Therapeutics, Inc. | -8.54 Million USD | 640.162% |
| Incyte Corporation | -3.17 Billion USD | 101.453% |
| IO Biotech, Inc. | -140.69 Million USD | 132.798% |
| Jaguar Health, Inc. | 29.39 Million USD | -57.011% |
| Novavax, Inc. | -298.29 Million USD | 115.47% |
| Janux Therapeutics, Inc. | 5.33 Million USD | -764.662% |
| Opthea Limited | 28.15 Million USD | -63.889% |
| Ligand Pharmaceuticals Incorporated | -16.78 Million USD | 374.864% |
| ContextLogic Inc. | -232 Million USD | 119.891% |
| MiMedx Group, Inc. | -33.9 Million USD | 236.123% |
| Pyxis Oncology, Inc. | 10.19 Million USD | -352.643% |
| TransCode Therapeutics, Inc. | -2.31 Million USD | 2091.647% |
| NextCure, Inc. | -6.47 Million USD | 812.475% |
| Ocuphire Pharma, Inc. | -50.5 Million USD | 191.378% |
| Oncternal Therapeutics, Inc. | -6.37 Million USD | 823.421% |
| Outlook Therapeutics, Inc. | 12.16 Million USD | -279.396% |
| Vaxcyte, Inc. | -368.22 Million USD | 112.532% |
| PDS Biotechnology Corporation | -32.7 Million USD | 241.084% |
| Madrigal Pharmaceuticals, Inc. | 17.27 Million USD | -167.085% |
| Pharming Group N.V. | 109.8 Million USD | 57.973% |
| Pieris Pharmaceuticals, Inc. | -17.39 Million USD | 365.274% |
| Avidity Biosciences, Inc. | -175.23 Million USD | 126.335% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 349.176% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 349.176% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 749.958% |
| Sol-Gel Technologies Ltd. | -5.86 Million USD | 887.491% |
| Acelyrin, Inc. | -216.9 Million USD | 121.275% |
| Salarius Pharmaceuticals, Inc. | -5.61 Million USD | 922.546% |
| SELLAS Life Sciences Group, Inc. | -1.72 Million USD | 2776.74% |
| Summit Therapeutics Inc. | 34.67 Million USD | -33.088% |
| Sensei Biotherapeutics, Inc. | -6.8 Million USD | 778.333% |
| Senti Biosciences, Inc. | 1.74 Million USD | -2552.126% |
| Stoke Therapeutics, Inc. | -184.6 Million USD | 124.997% |
| Syros Pharmaceuticals, Inc. | -77.45 Million USD | 159.582% |
| Alaunos Therapeutics, Inc. | -6.06 Million USD | 861.25% |
| Telomir Pharmaceuticals, Inc. Common Stock | 99.76 Thousand USD | -46153.846% |
| Entrada Therapeutics, Inc. | 628 Thousand USD | -7248.248% |
| VistaGen Therapeutics, Inc. | -117.04 Million USD | 139.426% |
| Wave Life Sciences Ltd. | -168.23 Million USD | 127.43% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 58.377% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 707.517% |
| Barinthus Biotherapeutics plc | -129.11 Million USD | 135.741% |
| Psyence Biomedical Ltd. | 6.89 Million USD | -569.321% |
| Phathom Pharmaceuticals, Inc. | -242.36 Million USD | 119.04% |
| Immix Biopharma, Inc. | -17.5 Million USD | 363.55% |
| Keros Therapeutics, Inc. | -316.7 Million USD | 114.571% |
| MEI Pharma, Inc. | -3.7 Million USD | 1345.533% |
| Windtree Therapeutics, Inc. | 12.51 Million USD | -268.851% |
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | 71.469% |
| Rigel Pharmaceuticals, Inc. | 27.79 Million USD | -66.038% |
| Fortress Biotech, Inc. | 7.66 Million USD | -502.048% |
| Precigen, Inc. | -481 Thousand USD | 9693.971% |
| Clearside Biomedical, Inc. | 14.08 Million USD | -227.725% |
| AlloVir, Inc. | -62.69 Million USD | 173.609% |
| C4 Therapeutics, Inc. | -55.61 Million USD | 182.977% |
| Fate Therapeutics, Inc. | 61.66 Million USD | 25.166% |
| ImmuCell Corporation | 10.99 Million USD | -319.878% |
| IDEAYA Biosciences, Inc. | -154.14 Million USD | 129.937% |
| Onconetix, Inc. | 5.33 Million USD | -765.564% |
| PureTech Health plc | -167.19 Million USD | 127.6% |
| VYNE Therapeutics Inc. | -30.46 Million USD | 251.5% |
| Elevation Oncology, Inc. | -19.11 Million USD | 341.38% |
| Kintara Therapeutics, Inc. | -4.9 Million USD | 1040.049% |
| Seer, Inc. | -4.24 Million USD | 1188.373% |
| Verrica Pharmaceuticals Inc. | -24.03 Million USD | 291.983% |
| Innoviva, Inc. | 255.56 Million USD | 81.943% |
| Aadi Bioscience, Inc. | -55.86 Million USD | 182.606% |
| ESSA Pharma Inc. | -33.62 Million USD | 237.254% |
| GlycoMimetics, Inc. | -40.98 Million USD | 212.596% |
| GT Biopharma, Inc. | -1.02 Million USD | 4619.785% |
| Inhibrx Biosciences, Inc. | -67.78 Million USD | 168.08% |
| Akebia Therapeutics, Inc. | 61.25 Million USD | 24.667% |
| Catalyst Pharmaceuticals, Inc. | -134.07 Million USD | 134.418% |
| Longboard Pharmaceuticals, Inc. | -13.85 Million USD | 433.047% |
| Orchestra BioMed Holdings, Inc. | -28.87 Million USD | 259.833% |
| Alzamend Neuro, Inc. | -75.33 Thousand USD | 61356.538% |
| Rocket Pharmaceuticals, Inc. | -30.86 Million USD | 249.527% |
| Aptose Biosciences Inc. | -8.19 Million USD | 663.121% |
| ZyVersa Therapeutics, Inc. | -3.12 Million USD | 1574.808% |
| Soligenix, Inc. | -4.95 Million USD | 1031.962% |
| Century Therapeutics, Inc. | 847 Thousand USD | -5348.288% |
| Kura Oncology, Inc. | -20.11 Million USD | 329.382% |
| TScan Therapeutics, Inc. | -40.92 Million USD | 212.757% |
| Intensity Therapeutics, Inc. | -8.39 Million USD | 649.5% |
| Ocean Biomedical, Inc. | 1.82 Million USD | -2433.19% |
| CytomX Therapeutics, Inc. | -3.19 Million USD | 1543.447% |
| Autolus Therapeutics plc | -186.59 Million USD | 124.731% |
| Mineralys Therapeutics, Inc. | -49.3 Million USD | 193.597% |
| EyePoint Pharmaceuticals, Inc. | -275.79 Million USD | 116.732% |
| Eterna Therapeutics Inc. | 34.26 Million USD | -34.665% |
| Adaptive Biotechnologies Corporation | 164.36 Million USD | 71.925% |
| GRI Bio, Inc. | -1.79 Million USD | 2672.297% |
| Xenetic Biosciences, Inc. | -8.98 Million USD | 613.712% |
| Tenaya Therapeutics, Inc. | -33.25 Million USD | 238.759% |
| IGM Biosciences, Inc. | -72.6 Million USD | 163.558% |
| INmune Bio, Inc. | -25.41 Million USD | 281.602% |
| Heron Therapeutics, Inc. | 150.95 Million USD | 69.429% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 191.093% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 383.993% |
| Entero Therapeutics, Inc. | -2.88 Million USD | 1699.59% |
| Milestone Pharmaceuticals Inc. | 38.01 Million USD | -21.392% |
| X4 Pharmaceuticals, Inc. | -41.18 Million USD | 212.048% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -44.729% |
| Coherus BioSciences, Inc. | 377.95 Million USD | 87.79% |
| Verastem, Inc. | -37.27 Million USD | 223.792% |
| Abeona Therapeutics Inc. | -9.07 Million USD | 608.619% |
| Pliant Therapeutics, Inc. | -51.86 Million USD | 188.98% |
| Tonix Pharmaceuticals Holding Corp. | -15.13 Million USD | 404.903% |
| Histogen Inc. | -7.48 Million USD | 716.362% |
| Aprea Therapeutics, Inc. | -21.6 Million USD | 313.576% |
| Surrozen, Inc. | -32.66 Million USD | 241.278% |
| Organovo Holdings, Inc. | -1.5 Million USD | 3162.177% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 1197.826% |
| Ovid Therapeutics Inc. | 18.96 Million USD | -143.389% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | -1664.029% |
| CASI Pharmaceuticals, Inc. | 4.15 Million USD | -1010.371% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.38 Million USD | 650.605% |
| Centessa Pharmaceuticals plc | -43.44 Million USD | 206.227% |
| Hepion Pharmaceuticals, Inc. | -14.57 Million USD | 416.577% |
| Arcturus Therapeutics Holdings Inc. | -316.78 Million USD | 114.567% |
| BioRestorative Therapies, Inc. | -722.06 Thousand USD | 6491.02% |
| Apollomics, Inc. | -27.39 Million USD | 268.45% |
| Amarin Corporation plc | -191.04 Million USD | 124.156% |
| Mesoblast Limited | 55.96 Million USD | 17.54% |
| Turnstone Biologics Corp. | -14.58 Million USD | 416.422% |
| Kymera Therapeutics, Inc. | -25.29 Million USD | 282.457% |
| Synaptogenix, Inc. | -28.66 Million USD | 261.007% |
| Tiziana Life Sciences Ltd | -936 Thousand USD | 5030.235% |
| Aurinia Pharmaceuticals Inc. | 48.73 Million USD | 5.305% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 5452.928% |
| Monopar Therapeutics Inc. | -7.26 Million USD | 735.102% |
| Exelixis, Inc. | -73.05 Million USD | 163.172% |
| Better Therapeutics, Inc. | -860 Thousand USD | 5465.93% |
| Nurix Therapeutics, Inc. | -24.01 Million USD | 292.175% |
| Apellis Pharmaceuticals, Inc. | -241.37 Million USD | 119.119% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -6169.411% |
| Dermata Therapeutics, Inc. | -7.43 Million USD | 720.411% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | -3579.984% |
| Gritstone bio, Inc. | 39.49 Million USD | -16.857% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 154.871% |
| TNF Pharmaceuticals, Inc. | -2.63 Million USD | 1853.212% |
| Avid Bioservices, Inc. | 169.72 Million USD | 72.811% |
| Insmed Incorporated | 721.62 Million USD | 93.605% |
| Virpax Pharmaceuticals, Inc. | -9.14 Million USD | 604.807% |
| MediWound Ltd. | -5.32 Million USD | 967.099% |
| OmniAb, Inc. | 9.2 Million USD | -401.434% |
| Alector, Inc. | -35.63 Million USD | 229.492% |
| Seres Therapeutics, Inc. | 85.97 Million USD | 46.323% |
| Checkpoint Therapeutics, Inc. | -4.92 Million USD | 1036.425% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | -248.569% |
| Zai Lab Limited | -775 Million USD | 105.954% |
| Revance Therapeutics, Inc. | 340.55 Million USD | 86.449% |
| Aura Biosciences, Inc. | -21.52 Million USD | 314.388% |
| Lyell Immunopharma, Inc. | -82.48 Million USD | 155.949% |
| Immunic, Inc. | -45.34 Million USD | 201.78% |
| Tarsus Pharmaceuticals, Inc. | -193.21 Million USD | 123.884% |
| Veracyte, Inc. | -203.82 Million USD | 122.641% |
| InMed Pharmaceuticals Inc. | 638.29 Million USD | 92.77% |
| FibroGen, Inc. | 56.76 Million USD | 18.708% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -418.214% |
| Adial Pharmaceuticals, Inc. | -2.82 Million USD | 1732.319% |
| Sonnet BioTherapeutics Holdings, Inc. | -2.07 Million USD | 2328.949% |
| Jazz Pharmaceuticals plc | 4.59 Billion USD | 98.995% |
| Cyclacel Pharmaceuticals, Inc. | -3.34 Million USD | 1481.233% |
| Amylyx Pharmaceuticals, Inc. | -165.96 Million USD | 127.805% |
| TG Therapeutics, Inc. | 17.86 Million USD | -158.353% |
| Galecto, Inc. | -21.21 Million USD | 317.51% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 294.017% |
| Fortrea Holdings Inc. | 1.56 Billion USD | 97.06% |
| KalVista Pharmaceuticals, Inc. | -24.47 Million USD | 288.571% |
| Aptevo Therapeutics Inc. | -11.5 Million USD | 501.034% |
| XBiotech Inc. | -200.02 Million USD | 123.071% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 154.871% |
| Lyra Therapeutics, Inc. | 4.52 Million USD | -919.148% |
| Foghorn Therapeutics Inc. | -35.26 Million USD | 230.865% |
| Y-mAbs Therapeutics, Inc. | -77.21 Million USD | 159.762% |
| Theravance Biopharma, Inc. | 5.69 Million USD | -710.877% |
| Ultragenyx Pharmaceutical Inc. | -170.41 Million USD | 127.079% |
| Metagenomi, Inc. Common Stock | -92.37 Million USD | 149.957% |
| Vaxxinity, Inc. | 10.13 Million USD | -355.458% |
| BioCryst Pharmaceuticals, Inc. | 736.26 Million USD | 93.732% |
| Gain Therapeutics, Inc. | -10.76 Million USD | 528.575% |
| Cartesian Therapeutics, Inc. | -65.95 Million USD | 169.966% |
| NexImmune, Inc. | -3.13 Million USD | 1572.631% |
| Creative Medical Technology Holdings, Inc. | -3.45 Million USD | 1436.559% |
| Marker Therapeutics, Inc. | -15.11 Million USD | 405.378% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 270.284% |
| Chemomab Therapeutics Ltd. | -8.97 Million USD | 614.112% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | 37143.548% |
| RAPT Therapeutics, Inc. | -40.57 Million USD | 213.741% |
| Ainos, Inc. | 4.07 Million USD | -1031.629% |
| Pluri Inc. | 22.82 Million USD | -102.142% |
| Prothena Corporation plc | -608.34 Million USD | 107.586% |
| Adaptimmune Therapeutics plc | -118.75 Million USD | 138.859% |
| Celularity Inc. | 65.19 Million USD | 29.212% |
| Rallybio Corporation | -24.1 Million USD | 291.465% |
| Cue Biopharma, Inc. | -33.81 Million USD | 236.453% |
| MeiraGTx Holdings plc | -40.3 Million USD | 214.503% |
| Omeros Corporation | 331.17 Million USD | 86.066% |
| Humacyte, Inc. | -22.48 Million USD | 305.225% |
| Immunocore Holdings plc | -358.59 Million USD | 112.869% |
| Cocrystal Pharma, Inc. | -24.57 Million USD | 287.78% |
| Cidara Therapeutics, Inc. | -30.9 Million USD | 249.338% |
| Blueprint Medicines Corporation | 702.83 Million USD | 93.434% |
| CalciMedica, Inc. | -5.53 Million USD | 934.485% |
| Cabaletta Bio, Inc. | -188.22 Million USD | 124.518% |
| Marinus Pharmaceuticals, Inc. | -10.21 Million USD | 551.801% |
| Scholar Rock Holding Corporation | -40.03 Million USD | 215.261% |
| Sana Biotechnology, Inc. | -33.25 Million USD | 238.775% |
| Pulmatrix, Inc. | -10.41 Million USD | 542.997% |
| Elicio Therapeutics, Inc. | -5.97 Million USD | 872.076% |
| Vigil Neuroscience, Inc. | -38.14 Million USD | 220.987% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 141.424% |
| Adlai Nortye Ltd. American Depositary Shares | -59.94 Million USD | 176.984% |
| Cytokinetics, Incorporated | 642.37 Million USD | 92.816% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 892.495% |
| Nutriband Inc. | -251.65 Thousand USD | 18437.261% |
| Protara Therapeutics, Inc. | -34.11 Million USD | 235.253% |
| Vor Biopharma Inc. | 4.3 Million USD | -973.186% |
| Roivant Sciences Ltd. | -6.03 Billion USD | 100.765% |
| Evogene Ltd. | -19.63 Million USD | 335.036% |
| ProKidney Corp. | -56.23 Million USD | 182.06% |
| Applied Therapeutics, Inc. | -48.67 Million USD | 194.812% |
| Hoth Therapeutics, Inc. | -9.23 Million USD | 599.578% |
| BridgeBio Pharma, Inc. | 1.36 Billion USD | 96.617% |
| CorMedix Inc. | -43.05 Million USD | 207.188% |
| BioLineRx Ltd. | 7.33 Million USD | -529.049% |
| Tango Therapeutics, Inc. | -27.46 Million USD | 268.021% |
| Atai Life Sciences N.V. | -28.55 Million USD | 261.59% |
| Renovaro Biosciences Inc. | 2.23 Million USD | -1968.881% |
| Aerovate Therapeutics, Inc. | -22.81 Million USD | 302.257% |
| Zentalis Pharmaceuticals, Inc. | 17.73 Million USD | -160.203% |
| Sagimet Biosciences Inc. | -75.07 Million USD | 161.469% |
| MediciNova, Inc. | -50.78 Million USD | 190.87% |
| Praxis Precision Medicines, Inc. | -78.8 Million USD | 158.558% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 205243.365% |
| GeoVax Labs, Inc. | -6.45 Million USD | 815.17% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 123.094% |
| Biomea Fusion, Inc. | -166.57 Million USD | 127.704% |
| PTC Therapeutics, Inc. | -178.97 Million USD | 125.784% |
| Mereo BioPharma Group plc | -51.46 Million USD | 189.66% |
| Cullinan Oncology, Inc. | -94.84 Million USD | 148.656% |
| Syndax Pharmaceuticals, Inc. | -293.75 Million USD | 115.709% |
| Absci Corporation | -72.59 Million USD | 163.565% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -910.666% |
| 4D Molecular Therapeutics, Inc. | -234.43 Million USD | 119.684% |
| Dyne Therapeutics, Inc. | -94.21 Million USD | 148.983% |
| Kiniksa Pharmaceuticals, Ltd. | -95.69 Million USD | 148.222% |
| Ventyx Biosciences, Inc. | -39.07 Million USD | 218.105% |
| Allakos Inc. | -24.97 Million USD | 284.773% |
| Imunon, Inc. | -4.21 Million USD | 1195.126% |
| Fulcrum Therapeutics, Inc. | -14.74 Million USD | 413.031% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 134.082% |
| BioAtla, Inc. | -109.01 Million USD | 142.332% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -6169.411% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | 5014.483% |
| Allogene Therapeutics, Inc. | 11.96 Million USD | -285.651% |
| Larimar Therapeutics, Inc. | -21.2 Million USD | 317.644% |
| XOMA Corporation | -29 Million USD | 259.128% |
| Kezar Life Sciences, Inc. | -16.56 Million USD | 378.665% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 611.835% |
| aTyr Pharma, Inc. | -7.44 Million USD | 719.506% |
| Aligos Therapeutics, Inc. | -124.63 Million USD | 137.025% |
| Akero Therapeutics, Inc. | -208.16 Million USD | 122.169% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 156.429% |
| Eliem Therapeutics, Inc. | -92.76 Million USD | 149.747% |
| EyeGate Pharmaceuticals, Inc. | -859.18 Thousand USD | 5471.026% |
| Akari Therapeutics, Plc | -3.84 Million USD | 1300.182% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -2743.508% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 96.658% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 3983.986% |
| UroGen Pharma Ltd. | 4.39 Million USD | -950.945% |
| Sutro Biopharma, Inc. | 113.48 Million USD | 59.335% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | -64026.9% |
| Orgenesis Inc. | 21.78 Million USD | -111.839% |
| Entera Bio Ltd. | -10.62 Million USD | 534.161% |
| GH Research PLC | -78.07 Million USD | 159.104% |
| Lisata Therapeutics, Inc. | -22.28 Million USD | 307.049% |
| Reneo Pharmaceuticals, Inc. | -26.65 Million USD | 273.101% |
| Xencor, Inc. | 29.64 Million USD | -55.671% |
| 60 Degrees Pharmaceuticals, Inc. | -1.96 Million USD | 2442.711% |
| Replimune Group, Inc. | 1.41 Million USD | -3168.201% |
| Coeptis Therapeutics Holdings, Inc. | -244.9 Thousand USD | 18942.586% |
| Vanda Pharmaceuticals Inc. | -126.41 Million USD | 136.504% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 3983.986% |
| Portage Biotech Inc. | -4.98 Million USD | 1026.461% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 205243.365% |
| Olema Pharmaceuticals, Inc. | -66.12 Million USD | 169.791% |
| OncoCyte Corporation | -6.56 Million USD | 803.139% |
| Qualigen Therapeutics, Inc. | 897.41 Thousand USD | -5042.225% |
| Processa Pharmaceuticals, Inc. | -4.55 Million USD | 1112.963% |
| Purple Biotech Ltd. | -14.13 Million USD | 426.404% |
| CollPlant Biotechnologies Ltd. | -23.75 Million USD | 294.254% |
| scPharmaceuticals Inc. | -6.54 Million USD | 805.073% |
| ProMIS Neurosciences, Inc. | -16.69 Million USD | 376.459% |
| HilleVax, Inc. | -165.48 Million USD | 127.886% |
| NeuroSense Therapeutics Ltd. | -2.53 Million USD | 1918.243% |
| Tharimmune, Inc. | -10.93 Million USD | 521.998% |
| Genprex, Inc. | -6.73 Million USD | 784.915% |
| Neumora Therapeutics, Inc. Common Stock | -368.8 Million USD | 112.513% |
| Atossa Therapeutics, Inc. | -88.46 Million USD | 152.167% |
| XTL Biopharmaceuticals Ltd. | -1.4 Million USD | 3393.862% |
| Virios Therapeutics, Inc. | -3.31 Million USD | 1491.25% |
| OKYO Pharma Limited | -826.84 Thousand USD | 5681.074% |
| Savara Inc. | 153 Thousand USD | -30061.438% |
| Curis, Inc. | -23.88 Million USD | 293.189% |
| Daré Bioscience, Inc. | -5.15 Million USD | 994.684% |
| Carmell Therapeutics Corporation | -776.01 Thousand USD | 6046.686% |
| Titan Pharmaceuticals, Inc. | -6.2 Million USD | 843.347% |
| Achieve Life Sciences, Inc. | 1.18 Million USD | -3794.262% |
| BeiGene, Ltd. | -2.25 Billion USD | 102.048% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | -274.008% |
| Revolution Medicines, Inc. Warrant | -608.2 Million USD | 107.587% |
| Protagonist Therapeutics, Inc. | -185.58 Million USD | 124.866% |
| Erasca, Inc. | -37.21 Million USD | 223.998% |
| bluebird bio, Inc. | 108.57 Million USD | 57.496% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 3683.139% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 87.816% |
| DBV Technologies S.A. | -126.98 Million USD | 136.34% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 3683.139% |
| Moderna, Inc. | -2.9 Billion USD | 101.587% |
| Vincerx Pharma, Inc. | -10.35 Million USD | 545.779% |
| Fresh Tracks Therapeutics, Inc. | -10.86 Million USD | 524.614% |
| Molecular Templates, Inc. | 707 Thousand USD | -6427.157% |
| Acrivon Therapeutics, Inc. Common Stock | -31.37 Million USD | 247.101% |
| Travere Therapeutics, Inc. | 346.6 Million USD | 86.686% |
| Monte Rosa Therapeutics, Inc. | -82.06 Million USD | 156.234% |
| Spruce Biosciences, Inc. | -91.73 Million USD | 150.307% |
| Celldex Therapeutics, Inc. | -32.27 Million USD | 242.994% |
| Cogent Biosciences, Inc. | -34.37 Million USD | 234.242% |
| MacroGenics, Inc. | -66.98 Million USD | 168.892% |
| RenovoRx, Inc. | -1.17 Million USD | 4034.101% |
| Adicet Bio, Inc. | -138.78 Million USD | 133.25% |
| Prime Medicine, Inc. | -27.94 Million USD | 265.159% |
| Aditxt, Inc. | 18.12 Million USD | -154.662% |
| Adagene Inc. | -87.62 Million USD | 152.663% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 1207.857% |
| Quantum-Si incorporated | -118.55 Million USD | 138.924% |
| Maravai LifeSciences Holdings, Inc. | 36 Million USD | -28.168% |
| Acurx Pharmaceuticals, Inc. | -7.47 Million USD | 717.418% |
| Voyager Therapeutics, Inc. | -48.5 Million USD | 195.131% |
| SciSparc Ltd. | -2.06 Million USD | 2334.722% |
| Vericel Corporation | 1.27 Million USD | -3513.704% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 484.824% |
| Minerva Neurosciences, Inc. | 41 Million USD | -12.542% |
| Generation Bio Co. | 31.44 Million USD | -46.741% |
| Astria Therapeutics, Inc. | -175.36 Million USD | 126.315% |
| Black Diamond Therapeutics, Inc. | -30.92 Million USD | 249.232% |
| Arcutis Biotherapeutics, Inc. | 116.59 Million USD | 60.42% |
| Invivyd, Inc. | -198.47 Million USD | 123.251% |
| Relay Therapeutics, Inc. | -90.27 Million USD | 151.121% |
| Quoin Pharmaceuticals, Ltd. | -2.39 Million USD | 2024.646% |
| Spero Therapeutics, Inc. | -70.79 Million USD | 165.189% |
| Artelo Biosciences, Inc. | -6.82 Million USD | 776.147% |
| 2seventy bio, Inc. | 181.71 Million USD | 74.605% |
| ADMA Biologics, Inc. | 90.06 Million USD | 48.763% |
| Clene Inc. | 3.34 Million USD | -1281.647% |
| Capricor Therapeutics, Inc. | -9.08 Million USD | 608.076% |
| Boundless Bio, Inc. Common Stock | -21.51 Million USD | 314.527% |
| GeoVax Labs, Inc. | -6.45 Million USD | 815.17% |
| Recursion Pharmaceuticals, Inc. | -344.12 Million USD | 113.41% |
| Citius Pharmaceuticals, Inc. | -25.99 Million USD | 277.491% |
| Contineum Therapeutics, Inc. Class A Common Stock | 177.66 Million USD | 74.026% |
| Relmada Therapeutics, Inc. | -4.09 Million USD | 1227.856% |
| Finch Therapeutics Group, Inc. | 5 Million USD | -822.571% |
| ALX Oncology Holdings Inc. | -5.2 Million USD | 985.909% |
| Vir Biotechnology, Inc. | -130.3 Million USD | 135.415% |
| Evaxion Biotech A/S | 5.28 Million USD | -772.865% |
| Ocular Therapeutix, Inc. | -112.56 Million USD | 140.995% |
| Verve Therapeutics, Inc. | -131.27 Million USD | 135.153% |
| Trevena, Inc. | 2.25 Million USD | -1943.711% |
| Surrozen, Inc. | -32.66 Million USD | 241.278% |
| Tyra Biosciences, Inc. | -51.51 Million USD | 189.588% |
| Cingulate Inc. | 3.08 Million USD | -1396.975% |
| Galmed Pharmaceuticals Ltd. | -2.93 Million USD | 1671.229% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -542.09% |
| Tenax Therapeutics, Inc. | -9.29 Million USD | 596.673% |
| Terns Pharmaceuticals, Inc. | -79.32 Million USD | 158.176% |
| ACADIA Pharmaceuticals Inc. | -131.45 Million USD | 135.106% |
| Connect Biopharma Holdings Limited | -105.54 Million USD | 143.724% |
| Clearmind Medicine Inc. | -3.94 Million USD | 1270.46% |
| Kronos Bio, Inc. | -36.05 Million USD | 227.994% |
| Bolt Biotherapeutics, Inc. | 9.4 Million USD | -390.456% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -3064.813% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 185.054% |
| Statera Biopharma, Inc. | 14.41 Million USD | -220.101% |
| ImmunityBio, Inc. | 618.22 Million USD | 92.536% |
| Korro Bio, Inc. | -132.94 Million USD | 134.712% |
| Kineta, Inc. | -4.54 Million USD | 1116.23% |
| BioVie Inc. | -17.73 Million USD | 360.242% |
| Codexis, Inc. | -43.27 Million USD | 206.646% |
| Celularity Inc. | 65.19 Million USD | 29.212% |
| Crinetics Pharmaceuticals, Inc. | -3.16 Million USD | 1556.201% |
| Celcuity Inc. | 6.78 Million USD | -580.282% |
| Virax Biolabs Group Limited | -3.36 Million USD | 1471.405% |
| Cibus, Inc. | -8.07 Million USD | 671.268% |
| Eledon Pharmaceuticals, Inc. | -4.22 Million USD | 1191.204% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | -909.781% |
| IN8bio, Inc. | -16.38 Million USD | 381.573% |
| Kodiak Sciences Inc. | -103.87 Million USD | 144.426% |
| Annexon, Inc. | -193.75 Million USD | 123.817% |
| Adverum Biotechnologies, Inc. | 36 Thousand USD | -128086.111% |
| Assembly Biosciences, Inc. | -17.49 Million USD | 363.712% |
| Avalo Therapeutics, Inc. | -3.51 Million USD | 1413.607% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 95.623% |
| Eyenovia, Inc. | 1.25 Million USD | -3566.237% |
| Puma Biotechnology, Inc. | 26.9 Million USD | -71.518% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 1522.973% |
| Xilio Therapeutics, Inc. | -33.24 Million USD | 238.8% |
| Arcellx, Inc. | -296.95 Million USD | 115.54% |
| Cardiff Oncology, Inc. | -19.5 Million USD | 336.578% |
| Enanta Pharmaceuticals, Inc. | -58.87 Million USD | 178.381% |
| Regulus Therapeutics Inc. | -20.72 Million USD | 322.642% |
| Moolec Science SA | 117.61 Thousand USD | -39135.308% |
| Acumen Pharmaceuticals, Inc. | -38.39 Million USD | 220.178% |
| Geron Corporation | 14.76 Million USD | -212.628% |
| LAVA Therapeutics N.V. | -37.91 Million USD | 221.702% |
| Royalty Pharma plc | 5.65 Billion USD | 99.184% |
| Atea Pharmaceuticals, Inc. | -141.42 Million USD | 132.631% |
| Greenwich LifeSciences, Inc. | -6.98 Million USD | 760.24% |
| TFF Pharmaceuticals, Inc. | -5.36 Million USD | 960.493% |
| Mersana Therapeutics, Inc. | -140.73 Million USD | 132.791% |
| Humacyte, Inc. | -22.48 Million USD | 305.225% |
| Structure Therapeutics Inc. | -124.33 Million USD | 137.114% |
| 89bio, Inc. | -289.05 Million USD | 115.965% |
| PMV Pharmaceuticals, Inc. | -25.24 Million USD | 282.818% |
| Avenue Therapeutics, Inc. | -1.78 Million USD | 2688.166% |
| Genelux Corporation | -6.89 Million USD | 768.894% |
| Trevi Therapeutics, Inc. | -31.05 Million USD | 248.579% |
| Lexicon Pharmaceuticals, Inc. | 83.59 Million USD | 44.8% |
| Notable Labs, Ltd. | -9.77 Million USD | 572.044% |
| Liquidia Corporation | -80.17 Million USD | 157.557% |
| Mustang Bio, Inc. | -3.73 Million USD | 1335.198% |
| Immunovant, Inc. | -635.22 Million USD | 107.265% |
| Quantum-Si incorporated | -118.55 Million USD | 138.924% |
| Arbutus Biopharma Corporation | -17.56 Million USD | 362.736% |
| DiaMedica Therapeutics Inc. | -4.14 Million USD | 1213.855% |
| Vera Therapeutics, Inc. | 8.02 Million USD | -474.897% |
| Acasti Pharma Inc. | -23 Million USD | 300.596% |
| MiNK Therapeutics, Inc. | -3.36 Million USD | 1470.474% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 383.993% |
| Xenon Pharmaceuticals Inc. | -137.74 Million USD | 133.503% |
| Elevai Labs, Inc. Common Stock | -3.11 Million USD | 1580.797% |
| NeuroBo Pharmaceuticals, Inc. | -22.23 Million USD | 307.57% |
| Tempest Therapeutics, Inc. | -18.56 Million USD | 348.516% |
| Soleno Therapeutics, Inc. | -169.27 Million USD | 127.261% |
| PepGen Inc. | -60.67 Million USD | 176.062% |
| Moleculin Biotech, Inc. | -22.97 Million USD | 300.849% |
| United Therapeutics Corporation | -507.7 Million USD | 109.089% |
| Nuvectis Pharma, Inc. | -19.12 Million USD | 341.279% |
| Solid Biosciences Inc. | -47.75 Million USD | 196.643% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 5452.928% |
| Immuneering Corporation | -54.94 Million USD | 183.991% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 1197.826% |
| Silo Pharma, Inc. | -3.52 Million USD | 1409.392% |
| Belite Bio, Inc | -87.27 Million USD | 152.878% |
| XOMA Corporation | -29 Million USD | 259.128% |
| ARS Pharmaceuticals, Inc. | -70.69 Million USD | 165.274% |
| Bionomics Limited | 227 Million USD | 79.672% |
| Apogee Therapeutics, Inc. | -116.28 Million USD | 139.685% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 1921.832% |
| uniQure N.V. | -102.95 Million USD | 144.824% |
| Cassava Sciences, Inc. | -121.13 Million USD | 138.095% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 1207.857% |
| Poseida Therapeutics, Inc. | 40.95 Million USD | -12.688% |
| Forte Biosciences, Inc. | -11.96 Million USD | 485.812% |
| Anebulo Pharmaceuticals, Inc. | -3.09 Million USD | 1591.403% |
| Enlivex Therapeutics Ltd. | 106 Thousand USD | -43434.906% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 1522.973% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -418.214% |
| FibroBiologics, Inc. Common Stock | -7.41 Million USD | 722.263% |
| Altimmune, Inc. | -134.48 Million USD | 134.313% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 76.701% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 1921.832% |
| Compugen Ltd. | -12.9 Million USD | 457.618% |
| Peak Bio, Inc. | 10.34 Million USD | -346.289% |
| Zevra Therapeutics, Inc. | -283 Thousand USD | 16406.36% |
| Benitec Biopharma Inc. | -50.58 Million USD | 191.232% |
| Spyre Therapeutics, Inc. | -104.33 Million USD | 144.228% |
| NKGen Biotech, Inc. Common Stock | 19.64 Million USD | -134.905% |
| Zura Bio Limited | -99.8 Million USD | 146.237% |
| PolyPid Ltd. | 6.17 Million USD | -647.925% |
| Aileron Therapeutics, Inc. | 74.12 Million USD | 37.74% |
| NKGen Biotech, Inc. Warrants | 19.64 Million USD | -134.905% |
| Instil Bio, Inc. | 75.35 Million USD | 38.763% |
| argenx SE | -2.02 Billion USD | 102.275% |
| Immunome, Inc. | -97.02 Million USD | 147.56% |
| Compass Therapeutics, Inc. | -22.49 Million USD | 305.143% |
| Verona Pharma plc | -220.44 Million USD | 120.934% |
| enGene Holdings Inc. Warrants | -71.74 Million USD | 164.323% |
| Shattuck Labs, Inc. | -121.42 Million USD | 138.005% |
| CervoMed Inc. | -7.79 Million USD | 692.171% |
| LENZ Therapeutics, Inc. | -185.49 Million USD | 124.877% |
| Plus Therapeutics, Inc. | -4.37 Million USD | 1155.271% |
| Dianthus Therapeutics, Inc. | -131.73 Million USD | 135.029% |
| Moolec Science SA | 117.61 Thousand USD | -39135.308% |
| Enveric Biosciences, Inc. | -2.28 Million USD | 2116.935% |
| Inovio Pharmaceuticals, Inc. | 15.89 Million USD | -190.262% |
| AnaptysBio, Inc. | -18.15 Million USD | 354.239% |
| Design Therapeutics, Inc. | -18.15 Million USD | 354.253% |
| Leap Therapeutics, Inc. | -70.38 Million USD | 165.567% |
| NeurAxis, Inc. | 145.7 Thousand USD | -31572.615% |
| Seelos Therapeutics, Inc. | 11.23 Million USD | -310.853% |
| Lumos Pharma, Inc. | -28.49 Million USD | 261.959% |
| Achilles Therapeutics plc | -126.92 Million USD | 136.358% |
| enGene Holdings Inc. Common Stock | -71.74 Million USD | 164.323% |
| 180 Life Sciences Corp. | -655.73 Thousand USD | 7137.5% |
| Opiant Pharmaceuticals, Inc. | -20.77 Million USD | 322.14% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -3064.813% |
| Nutriband Inc. | -251.65 Thousand USD | 18437.261% |
| ORIC Pharmaceuticals, Inc. | -13.17 Million USD | 450.368% |
| CG Oncology, Inc. Common stock | -7.44 Million USD | 720.255% |
| Fractyl Health, Inc. Common Stock | 340.19 Million USD | 86.435% |
| Rani Therapeutics Holdings, Inc. | 23.73 Million USD | -94.426% |
| MoonLake Immunotherapeutics | -447.47 Million USD | 110.313% |
| Palisade Bio, Inc. | -12.06 Million USD | 482.55% |
| Tourmaline Bio, Inc. | -140.31 Million USD | 132.889% |
| Beam Therapeutics Inc. | -262.72 Million USD | 117.565% |
| Neurogene Inc. | -131.95 Million USD | 134.972% |
| Mirum Pharmaceuticals, Inc. | 21.81 Million USD | -111.528% |
| AEON Biopharma, Inc. | -4.88 Million USD | 1045.635% |
| CARGO Therapeutics, Inc. Common Stock | -377.19 Million USD | 112.234% |
| Sesen Bio, Inc. | -112.55 Million USD | 141.0% |
| Enliven Therapeutics, Inc. | -99.86 Million USD | 146.212% |
| Kiora Pharmaceuticals, Inc. | -2.34 Million USD | 2065.548% |
| Iovance Biotherapeutics, Inc. | -39.02 Million USD | 218.247% |
| Taysha Gene Therapies, Inc. | -83.28 Million USD | 155.411% |
| Athira Pharma, Inc. | -88.99 Million USD | 151.851% |
| Vaccinex, Inc. | -1.28 Million USD | 3682.842% |
| HCW Biologics Inc. | 2.85 Million USD | -1515.409% |
| XOMA Corporation | -29 Million USD | 259.128% |
| Nektar Therapeutics | 210.24 Million USD | 78.05% |
| Arvinas, Inc. | -313.8 Million USD | 114.706% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -2743.508% |
| Merus N.V. | -192.88 Million USD | 123.925% |
| Omega Therapeutics, Inc. | 59.98 Million USD | 23.069% |
| Quince Therapeutics, Inc. | -6.93 Million USD | 765.134% |
| Rezolute, Inc. | -68.16 Million USD | 167.696% |
| Clene Inc. | 3.34 Million USD | -1281.647% |
| Indaptus Therapeutics, Inc. | -13.18 Million USD | 449.943% |
| BeyondSpring Inc. | -13.75 Million USD | 435.493% |
| Synlogic, Inc. | -6.68 Million USD | 790.307% |
| Allarity Therapeutics, Inc. | 1.13 Million USD | -3969.4% |
| Phio Pharmaceuticals Corp. | -8.45 Million USD | 645.795% |
| Peak Bio, Inc. | 10.34 Million USD | -346.289% |
| Werewolf Therapeutics, Inc. | -82.42 Million USD | 155.99% |
| Krystal Biotech, Inc. | -350.23 Million USD | 113.176% |
| Karyopharm Therapeutics Inc. | 124.12 Million USD | 62.822% |
| SpringWorks Therapeutics, Inc. | -168.99 Million USD | 127.307% |
| Lipella Pharmaceuticals Inc. | -3.15 Million USD | 1561.669% |
| MannKind Corporation | 143.89 Million USD | 67.931% |
| Ikena Oncology, Inc. | -109.15 Million USD | 142.276% |
| Cyclerion Therapeutics, Inc. | -7.57 Million USD | 709.523% |
| Gyre Therapeutics, Inc. | -33.1 Million USD | 239.417% |
| Gossamer Bio, Inc. | 180.35 Million USD | 74.413% |
| CohBar, Inc. | -5.93 Million USD | 878.1% |
| Cognition Therapeutics, Inc. | -29.74 Million USD | 255.126% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -910.666% |
| Legend Biotech Corporation | -949.39 Million USD | 104.861% |
| Mural Oncology plc | -255.84 Million USD | 118.037% |
| Biora Therapeutics, Inc. | 32.21 Million USD | -43.247% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 1079.633% |
| Disc Medicine, Inc. | -358.28 Million USD | 112.88% |
| Champions Oncology, Inc. | 4.81 Million USD | -858.998% |
| REGENXBIO Inc. | 54.76 Million USD | 15.741% |
| Ensysce Biosciences, Inc. | -268.9 Thousand USD | 17260.952% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 130.556% |
| Cellectar Biosciences, Inc. | -9.01 Million USD | 612.061% |
| Edgewise Therapeutics, Inc. | -80.68 Million USD | 157.195% |
| Vaxart, Inc. | -8.24 Million USD | 659.968% |
| PharmaCyte Biotech, Inc. | -50.17 Million USD | 191.963% |
| Aldeyra Therapeutics, Inc. | -127.16 Million USD | 136.289% |
| Cellectis S.A. | -43.85 Million USD | 205.226% |
| Longeveron Inc. | -2.9 Million USD | 1686.898% |
| Repare Therapeutics Inc. | -107.85 Million USD | 142.785% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 95.235% |
| Inozyme Pharma, Inc. | 12 Million USD | -284.43% |
| Revolution Medicines, Inc. | -608.2 Million USD | 107.587% |
| Nymox Pharmaceutical Corporation | -1.23 Million USD | 3851.789% |
| Third Harmonic Bio, Inc. | -265.11 Million USD | 117.406% |
| ArriVent BioPharma, Inc. Common Stock | -150.07 Million USD | 130.75% |
| AN2 Therapeutics, Inc. | -15.64 Million USD | 394.926% |
| Anixa Biosciences, Inc. | -740 Thousand USD | 6336.081% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 100.483% |
| Denali Therapeutics Inc. | -74.86 Million USD | 161.64% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 484.824% |
| Veru Inc. | 4.77 Million USD | -865.425% |
| Corvus Pharmaceuticals, Inc. | -11.24 Million USD | 510.341% |
| Cingulate Inc. | 3.08 Million USD | -1396.975% |
| Passage Bio, Inc. | 4.58 Million USD | -906.478% |
| Context Therapeutics Inc. | -14.44 Million USD | 419.36% |
| Exicure, Inc. | 5.84 Million USD | -688.972% |
| Day One Biopharmaceuticals, Inc. | -230.37 Million USD | 120.031% |
| Oramed Pharmaceuticals Inc. | -39.57 Million USD | 216.621% |
| Scinai Immunotherapeutics Ltd. | 15.69 Million USD | -194.099% |
| Rhythm Pharmaceuticals, Inc. | -58.82 Million USD | 178.453% |
| Nuvalent, Inc. | -335.38 Million USD | 113.759% |
| ABVC BioPharma, Inc. | 1.73 Million USD | -2560.78% |
| Carisma Therapeutics, Inc. | -74.48 Million USD | 161.957% |
| Unicycive Therapeutics, Inc. | -8.89 Million USD | 619.089% |
| OmniAb, Inc. | 9.2 Million USD | -401.434% |
| Anew Medical, Inc. | 1.43 Million USD | -3121.51% |
| Fennec Pharmaceuticals Inc. | 16.38 Million USD | -181.698% |
| Lipocine Inc. | -4.75 Million USD | 1070.577% |
| Lexeo Therapeutics, Inc. Common Stock | -109.82 Million USD | 142.018% |
| Nautilus Biotechnology, Inc. | 15.23 Million USD | -202.981% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 191.093% |
| G1 Therapeutics, Inc. | 24.89 Million USD | -85.389% |
| Bellerophon Therapeutics, Inc. | -6.72 Million USD | 786.609% |
| Sage Therapeutics, Inc. | -65.82 Million USD | 170.103% |
| Ocugen, Inc. | -32.52 Million USD | 241.899% |
| Mind Medicine (MindMed) Inc. | -85.57 Million USD | 153.926% |
| Q32 Bio Inc. | -37.94 Million USD | 221.606% |
| Brainstorm Cell Therapeutics Inc. | -628 Thousand USD | 7448.248% |
| Alumis Inc. Common Stock | -13.52 Million USD | 441.097% |
| Equillium, Inc. | -22.39 Million USD | 306.087% |
| Kyverna Therapeutics, Inc. | -25.56 Million USD | 280.487% |
| Coya Therapeutics, Inc. | -32.62 Million USD | 241.439% |
| CNS Pharmaceuticals, Inc. | -247.91 Thousand USD | 18714.041% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 65.573% |
| Evelo Biosciences, Inc. | 3.19 Million USD | -1342.996% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | -13950.316% |
| Dominari Holdings Inc. | 195 Thousand USD | -23565.128% |
| Edesa Biotech, Inc. | -5.26 Million USD | 976.168% |
| vTv Therapeutics Inc. | -8.91 Million USD | 617.517% |
| Bio-Techne Corporation | 267.74 Million USD | 82.765% |
| Agios Pharmaceuticals, Inc. | -16.2 Million USD | 384.7% |
| Harmony Biosciences Holdings, Inc. | -118.09 Million USD | 139.076% |
| Prelude Therapeutics Incorporated | -8.4 Million USD | 649.173% |
| Candel Therapeutics, Inc. | -12.65 Million USD | 464.77% |
| iTeos Therapeutics, Inc. | -245.11 Million USD | 118.826% |
| Nkarta, Inc. | 57.29 Million USD | 19.463% |
| BioCardia, Inc. | 212 Thousand USD | -21667.453% |
| Iterum Therapeutics plc | 13.43 Million USD | -243.407% |